시장보고서

상품코드

1877432

발기부전 시장 : 용도별, 치료 유형별, 제품 유형별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 점유율 및 예측(2025-2032년)

Erectile Dysfunction Market, By Application, By Therapy Type, By Product Type, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 397 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

발기부전 시장 규모는 2024년 25억 6,787만 달러로 평가되었고, 2025년부터 2032년까지 연평균 8.2%의 성장률을 보일 것으로 예측됩니다.

발기부전(ED)은 만족스러운 성행위를 위해 충분한 발기를 달성하거나 유지하는 데 지속적으로 어려움을 겪는 상태를 말합니다. 혈관, 신경, 호르몬, 심리적 요인 등 여러 요인이 관여하는 질환으로 남성의 신체적, 정신적 건강에 심각한 영향을 미칩니다. 심혈관계 질환, 당뇨병과 같은 만성질환 증가와 운동부족 생활습관 및 스트레스 관련 질환의 확산은 ED를 유발하는 주요 요인으로 작용하고 있습니다. 한편, 비아그라, 시알리스 등 블록버스터 의약품의 특허 보호 만료로 인한 가격 하락과 제네릭 의약품과의 치열한 경쟁은 시장 확대를 억제하는 요인으로 작용하고 있습니다. 그러나 차세대 경구용 치료제, 줄기세포 치료, 그리고 온라인상에서 비밀을 보장하는 상담 및 처방을 제공할 수 있는 디지털 헬스 플랫폼의 개발이 새로운 기회로 떠오르고 있습니다. 이러한 혁신 기술과 남성 건강의 일부로서 성적인 웰빙에 대한 인식이 확대되면서 발기부전 치료제 시장의 장기적인 성장과 현대화를 촉진할 것으로 예측됩니다.

발기부전 시장 역학

생활습관병 증가로 시장 성장 촉진

생활습관병 증가 추세는 발기부전 시장을 견인할 것으로 예측됩니다. 생활습관병은 주로 부적절한 식습관, 운동 부족, 흡연, 과음 등 건강에 해로운 습관으로 인해 발생하는 건강 상태를 말합니다. 생활습관병 증가는 좌식 생활, 부적절한 식습관, 스트레스, 흡연과 과음 등 건강에 해로운 습관 증가에 기인합니다. 발기부전(ED)은 심혈관 질환이나 당뇨병과 같은 생활습관병의 조기 경고 신호로, 신속한 의료적 대응과 건강한 생활습관 선택의 중요성을 강조하고 있습니다. 예를 들어, 영국에 본부를 둔 비영리단체 '세계비만연맹'이 2022년 5월 발표한 보고서에 따르면, 2030년까지 전 세계적으로 10억 명(여성 5명 중 1명, 남성 7명 중 1명)이 비만일 것으로 예상되며, 2035년까지 40억 명(세계 인구의 51%)에 달할 것으로 전망하고 있습니다. 예상되고 있습니다. 그 결과, 생활습관병 증가는 발기부전 치료 산업의 성장을 가속할 것입니다.

발기부전 시장 : 세분화 분석

세계 발기부전 시장은 용도별, 치료 유형별, 제품 유형별, 유통 채널별, 지역별로 분류됩니다.

용도별로는 경구용 의약품이 2025년 기준 세계 발기부전 치료제 시장에서 가장 큰 수익 부문을 차지할 것으로 예측됩니다. 이는 시알리스, 비아그라, 비아그라 등 경구용 약물의 사용 증가에 기인합니다. 이러한 약물은 자가 투여가 가능하고 비용 효율적이며, 시장 기업간의 제휴 및 협업이 증가하고 있기 때문입니다. 예를 들어, 2022년 5월에는 라보라토리오스 루비오사가 처방약 '반돌(실데나필 경구 현탁액)'을 아스파르고 랩토리스(Aspargo Laboratories)에 매각했습니다. 반돌은 발기부전 치료에 사용됩니다. 이번 인수와 동시에 아스파르고는 루비오와 판매 계약을 체결하고, 스페인 시장에서 반달의 판매 및 홍보를 지속할 예정입니다.

유통 채널별로는 온라인 약국이 전 세계 발기부전 치료제 시장에서 가장 중요한 판매 채널로 부상하고 있습니다. 이는 발기부전 발생률 증가로 인해 보다 빠르고 효과적인 결과를 얻기 위한 대체 치료법의 채택이 증가하고 있으며, 첨단 플랫폼의 출시가 증가하고 있기 때문입니다. 예를 들어, 2023년 10월에는 안전한 원격 의료 플랫폼을 통해 다양한 남성 건강 및 웰니스 제품을 개발, 마케팅, 판매하는 기업 망고슈티컬스(Mangoceuticals, Inc.)가 자사 브랜드인 망고(Mango)의 발기부전(ED) 치료제를 포함한 자사 브랜드 '망고(Mango)'의 제품군에 대해 새롭게 개편된 웹사이트를 통해 제휴 마케팅 프로그램을 시작할 예정입니다.

발기부전 시장 - 지역별 분석

북미는 발기부전(ED) 치료제 시장의 주요 수익원입니다. 이는 높은 응급실 유병률, 선진화된 의료 인프라, 그리고 환자 교육의 보급에 기인합니다. 이 지역은 강력한 R&D 역량과 더불어 화이자(비아그라), 일라이 릴리(시알리스)와 같은 주요 제약사의 존재로 인해 새로운 제형과 병용요법을 통한 혁신이 지속적으로 이루어지고 있습니다. 높은 가처분 소득, 의료 서비스 접근성 향상, 유리한 상환 제도가 결합되어 장기적인 시장 수요를 뒷받침하고 있습니다. 그러나 특허만료와 제네릭 의약품의 보급 확대로 경쟁이 심화되어 가격 전략에 영향을 미치고 있습니다. Oxford Academic(2024년 2월)에 따르면, 북미의 발기부전 평균 유병률은 20.7%이며, 모든 연령대와 관련 동반 질환을 가진 개인에서 꾸준히 증가하고 있어 이 지역의 임상적, 상업적 중요성이 지속되고 있음을 보여줍니다.

미국 발기부전 시장 - 국가별 분석

미국은 북미 ED 치료제 시장에서 중요한 역할을 담당하고 있습니다. 고령화 인구 증가, 당뇨병, 고혈압 등 생활습관병, ED 치료 옵션에 대한 인식 개선 등이 시장 성장에 기여하고 있습니다. 화이자와 일라이 릴리 등의 제약사들은 소매 약국 및 온라인 플랫폼을 포함한 다양한 유통 채널을 통해 실데나필(비아그라), 타다라필(시알리스), 발데나필(레비트라) 등의 의약품을 제공하며 큰 존재감을 드러내고 있습니다. 예를 들어, 2023년 7월에는 헤레온이 퓨쳐라의 약물 무함유 MED3000 겔(FDA로부터 신규 의료기기로 승인받은 제품)의 상용화 계약을 체결하고 미국 OTC 발기부전치료제 시장에 진출했습니다. 퓨처라의 외용제(미국 식품의약국으로부터 시판용 의약품 의료기기로 승인 받은 지 얼마 되지 않은)의 초기 상용화 비용은 400만 달러에 달했습니다.

발기부전 시장 : 경쟁 구도

화이자, 일라이 릴리, 바이엘, 비아트리스, 테바 제약공업, 보스턴 사이언티픽 등이 발기부전 치료제 시장의 주요 기업입니다. 이들 기업은 경구용 의약품, 음경 임플란트, 줄기세포 치료, 충격파 치료 등 신흥 재생의료 분야의 혁신을 통해 제품 라인의 다양화를 적극적으로 추진하고 있습니다. 비아그라, 시알리스와 같은 블록버스터 의약품의 특허가 만료되고 제네릭 의약품과 바이오시밀러가 시장에 진입할 수 있게 되면서 경쟁은 더욱 치열해지고 있습니다. 또한, 전략적 제휴, 합병, 처방전 발급 및 진료를 위한 원격 의료 플랫폼과 같은 디지털 헬스 통합도 경쟁 역학에 영향을 미치고 있습니다. 전 세계적으로 증가하는 환자층의 요구에 부응하기 위해 이 분야는 혁신성, 접근성, 개인화된 치료 옵션을 우선시하고 있습니다. 예를 들어, 2024년 2월 페트로스 파마슈티컬스(Petros Pharmaceuticals)와 23andMe는 주요 AI 소프트웨어 제공업체와 협력하여 STENDRA(아바나필)의 일반의약품(OTC) 승인을 위한 자가 선택 연구에 첨단 기술을 도입했습니다. 이 AI 기반 도구는 스크리닝 정확도를 높이고, FDA 및 ACNU 가이드라인에 따라 안전한 의약품 접근을 보장하며, 페트로스의 OTC 전환을 가속화하기 위한 목적으로 개발되었습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 발기부전 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- Bayer AG
- Lilly
- Petros Pharmaceuticals, Inc.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceutical
- Sanofi
- Industries Ltd
- Lupin Limited
- Futura Medical
- Cure Pharmaceutical
- Sun Pharmaceutical Industries Ltd
- VIVUS, Inc.
- Auxilium Pharmaceuticals, Inc.
- Others

제13장 AnalystView의 전방위적 분석

LSH 25.12.19

Erectile Dysfunction Market size was valued at US$ 2,567.87 Million in 2024, expanding at a CAGR of 8.2% from 2025 to 2032.

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It is a multifactorial condition resulting from vascular, neurological, hormonal, or psychological causes that has a significant impact on men's physical and emotional health. The rising global prevalence of chronic diseases such as cardiovascular disorders and diabetes, both of which contribute significantly to ED, as well as sedentary lifestyles and stress-related conditions, is a key market driver. In contrast, the market is restrained by the loss of patent protection for blockbuster drugs such as Viagra and Cialis, which has resulted in price erosion and intense competition from generics. Nonetheless, an emerging opportunity is the development of next-generation oral therapies, stem-cell-based treatments, and digital health platforms that provide confidential online consultations and prescriptions. These innovations, combined with a growing acceptance of sexual wellness as part of men's health, are expected to drive the erectile dysfunction market's long-term growth and modernization.

Erectile Dysfunction Market- Market Dynamics

Rising Prevalence of Lifestyle-Related Diseases To Propel Growth In The Market

The increasing prevalence of lifestyle-related diseases is expected to fuel the erectile dysfunction market. Lifestyle-related diseases are health conditions that are primarily caused by unhealthy habits such as poor diet, lack of exercise, smoking, and binge drinking. The rise in lifestyle-related diseases is attributed to increased sedentary behavior, poor dietary habits, stress, and unhealthy habits such as smoking and excessive alcohol consumption. Erectile dysfunction (ED) is an early warning sign for lifestyle-related diseases such as cardiovascular disease and diabetes, emphasizing the importance of prompt medical attention and healthier lifestyle choices. For instance, according to a report published in May 2022 by the World Obesity Federation, a non-profit organization based in the United Kingdom, by 2030, one billion people worldwide, including one in every five women and one in every seven men, are expected to be obese, rising to 4 billion people, or 51% of the global population, by 2035. As a result, the increasing prevalence of lifestyle-related diseases will drive growth in the erectile dysfunction industry.

Erectile Dysfunction Market- Segmentation Analysis:

The Global Erectile Dysfunction Market is segmented by Application, Therapy Type, Product Type, Distribution Channel and Region.

According to the Application, Oral medication is the highest revenue-generating segment in the global erectile dysfunction drugs market in 2025, owing to an increase in the use of oral medications such as Cialis, Stendra, Viagra, and others, which can be self-administered and are cost-effective, as well as increasing partnerships and collaborations among market players. For instance, in May 2022, Laboratorios Rubio S.A. sold the prescription medication BANDOL (sildenafil oral suspension) to Aspargo Laboratories, Inc. BANDOL is used to treat erectile dysfunction. Concurrently with this acquisition, Aspargo signed a distribution agreement with Rubio to continue marketing and promoting BANDOL in the Spanish market.

By Distribution Channel, Online pharmacies are the most important selling channel in the global erectile dysfunction drugs market, owing to the rising incidence of erectile dysfunction, which is driving the adoption of alternative treatments for faster and more effective results, as well as the increased launch of advanced platforms. For example, in October 2023, Mangoceuticals, Inc., a company dedicated to the development, marketing, and sale of a range of men's health and wellness products through a secure telemedicine platform, including its specially formulated erectile dysfunction (ED) medication under the brand name "Mango," will launch its affiliate marketing program via its newly revamped website.

Erectile Dysfunction Market- Geographical Insights

North America is a significant revenue-generating region in the erectile dysfunction (ED) drugs market, thanks to a high prevalence of ED, advanced healthcare infrastructure, and widespread patient education. The region benefits from strong R&D capabilities as well as the presence of leading pharmaceutical companies like Pfizer Inc. (Viagra) and Eli Lilly and Company (Cialis), which are constantly innovating through novel formulations and combination therapies. High disposable incomes, improved access to healthcare, and favorable reimbursement frameworks all contribute to long-term market demand. However, patent expirations and the increasing availability of generic alternatives have increased competition and influenced pricing strategies. According to Oxford Academic (February 2024), the average ED prevalence rate in North America was 20.7%, with a steady increase observed across age groups and among individuals with associated health comorbidities, highlighting the region's continued clinical and commercial importance.

United States Erectile Dysfunction Market- Country Insights

The United States makes a significant contribution to the North American erectile dysfunction drug market. A large aging population, lifestyle-related diseases such as diabetes and hypertension, and rising awareness of erectile dysfunction treatment options all contribute to market growth. Pharmaceutical companies such as Pfizer and Eli Lilly have a significant presence, providing medications such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) through a variety of distribution channels, including retail pharmacies and online platforms. For example, in July 2023, Haleon entered the US OTC erectile dysfunction market with a commercialization agreement for Futura's drug-free MED3000 gel, which was recently approved by the FDA as a de novo medical device. Futura's topical treatment, which was recently approved by the US Food and Drug Administration as an over-the-counter medical device, cost $4 million to commercialize initially.

Erectile Dysfunction Market- Competitive Landscape:

Pfizer Inc., Eli Lilly and Company, Bayer AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., and Boston Scientific Corporation are among the top Erectile Dysfunction (ED) market players. These companies are actively diversifying their product offerings with innovations in oral medications, penile implants, and emerging regenerative therapies like stem cell and shockwave treatments. The market is experiencing increased competition as patents for blockbuster drugs such as Viagra and Cialis expire, allowing generics and biosimilars to enter the marketplace. In addition, strategic collaborations, mergers, and digital health integrations such as telemedicine platforms for prescription and consultation are influencing competitive dynamics. To meet the needs of a growing global patient base, the landscape prioritizes innovation, accessibility, and personalized treatment options. For instance, in February 2024, Petros Pharmaceuticals and 23andMe collaborated with a major AI software provider to incorporate advanced technology into its Self-Selection Study for STENDRA (avanafil) OTC approval. The AI-driven tool aimed to improve screening accuracy, ensure safe medication access in accordance with FDA and ACNU guidelines, and accelerate Petros' path to OTC status.

Recent Developments:

In March 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI, a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class II-III.1 OPSYNVI(R) can be used for PAH patients who are treatment-naive or already taking an ERA, PDE5 inhibitor, or both.

In July 2024, Aspargo Labs, Inc., a speciality pharmaceutical and MedTech company focused on transforming drug delivery through innovative oral sprays, today announced the release of a Phase 1 study demonstrating that ASP-001, an investigative sildenafil oral spray in development for erectile dysfunction (ED), achieves absorption within five minutes, which is twice as fast as traditional sildenafil tablets.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL ERECTILE DYSFUNCTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Bayer AG
Lilly
Petros Pharmaceuticals, Inc.
Pfizer Inc.
GlaxoSmithKline PLC
Teva Pharmaceutical
Sanofi
Industries Ltd
Lupin Limited
Futura Medical
Cure Pharmaceutical
Sun Pharmaceutical Industries Ltd
VIVUS, Inc.
Auxilium Pharmaceuticals, Inc.
Others

GLOBAL ERECTILE DYSFUNCTION MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Parenteral
Oral

GLOBAL ERECTILE DYSFUNCTION MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

Drug Therapy
Device Therapy

GLOBAL ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Generic Drugs
Sildenafil
Vardenafil
Alprostadil
Tadalafil
Others
Branded Drugs
Cialis
Zydena
Viagra
Others

GLOBAL ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

GLOBAL ERECTILE DYSFUNCTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Erectile Dysfunction Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Erectile Dysfunction Market Snippet by Application
- 2.1.2. Erectile Dysfunction Market Snippet by Therapy Type
- 2.1.3. Erectile Dysfunction Market Snippet by Product Type
- 2.1.4. Erectile Dysfunction Market Snippet by Distribution Channel
- 2.1.5. Erectile Dysfunction Market Snippet by Country
- 2.1.6. Erectile Dysfunction Market Snippet by Region
2.2. Competitive Insights

3. Erectile Dysfunction Key Market Trends

3.1. Erectile Dysfunction Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Erectile Dysfunction Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Erectile Dysfunction Market Opportunities
3.4. Erectile Dysfunction Market Future Trends

4. Erectile Dysfunction Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Erectile Dysfunction Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Erectile Dysfunction Market Landscape

6.1. Erectile Dysfunction Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Erectile Dysfunction Market - By Application

7.1. Overview
- 7.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
- 7.1.2. Parenteral
- 7.1.3. Oral

8. Erectile Dysfunction Market - By Therapy Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
- 8.1.2. Drug Therapy
- 8.1.3. Device Therapy

9. Erectile Dysfunction Market - By Product Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
- 9.1.2. Generic Drugs
  - 9.1.2.1. Sildenafil
  - 9.1.2.2. Vardenafil
  - 9.1.2.3. Alprostadil
  - 9.1.2.4. Tadalafil
  - 9.1.2.5. Others
- 9.1.3. Branded Drugs
  - 9.1.3.1. Cialis
  - 9.1.3.2. Zydena
  - 9.1.3.3. Viagra
  - 9.1.3.4. Others

10. Erectile Dysfunction Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Online Pharmacies
- 10.1.4. Retail Pharmacies

11. Erectile Dysfunction Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Erectile Dysfunction Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Erectile Dysfunction Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Erectile Dysfunction Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Erectile Dysfunction Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Erectile Dysfunction Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Erectile Dysfunction Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Bayer AG
- 12.2.2. Lilly
- 12.2.3. Petros Pharmaceuticals, Inc.
- 12.2.4. Pfizer Inc.
- 12.2.5. GlaxoSmithKline PLC
- 12.2.6. Teva Pharmaceutical
- 12.2.7. Sanofi
- 12.2.8. Industries Ltd
- 12.2.9. Lupin Limited
- 12.2.10. Futura Medical
- 12.2.11. Cure Pharmaceutical
- 12.2.12. Sun Pharmaceutical Industries Ltd
- 12.2.13. VIVUS, Inc.
- 12.2.14. Auxilium Pharmaceuticals, Inc.
- 12.2.15. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us